Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBM801
- Development stage
- Phase 1
- Lead developer
- Shanghai Haohai Biological Technology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
LBM801 is an umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy developed by Shanghai Bosaimi Biotechnology and Shanghai Likangrui Bioengineering. It is designed for the treatment of knee osteoarthritis, a degenerative joint disease characterized by cartilage loss and inflammation. Administered via a single intra-articular injection, LBM801 aims to leverage the immunomodulatory, anti-inflammatory, and potential regenerative properties of MSCs to alleviate pain, improve joint function, and slow disease progression. The product is currently being evaluated in a Phase I clinical trial in China to determine its safety, tolerability, and preliminary efficacy across escalating doses.
Beyond the preview
Go deeper on LBM801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LBM801.